Crowley John F, Chairman & CEO, subtracted 14,500 shares of Amicus Therapeutics, Inc. (FOLD) from its portfolio at the rate of $8.01 per share valuing $116,073 on Oct 11. The insider left behind 735,694 shares of the company to its portfolio. Currently, the 1st Resistance Point for this stock is $9.01, with a 2nd Resistance Point sitting at $9.10. Meanwhile, this company’s stock has a 1st Support Level at $8.75 and a 2nd Support Level at $8.58. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Amicus Therapeutics, Inc. (FOLD) was $8.92. Amicus Therapeutics, Inc. (FOLD) stock has gained $0.49, or 5.81%, in the past five days. In the last full month, these shares have gained $1.21, or 15.69%. In the past three months, this stock’s price has fallen by -$2.91, or -24.60%. This year-to-date, Amicus Therapeutics, Inc. (FOLD) shares have lost -$0.66, or -6.89%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Amicus Therapeutics, Inc. (FOLD) stock, 50% of short-term indicators suggest that these shares are a “ Sell .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Sell .” Looking further ahead, 100% of long-term indicators suggest that this stock is a “ Sell .”
With 254,626 K shares outstanding, this company currently has a market capitalization of $2,215,246K. Amicus Therapeutics, Inc. (FOLD) generates $91,250 K in annual sales, amounting to annual net income of -$349,000 K. This stock has generated a 1-Year Total Return of -21.82%, a 3-Year Total Return of -5.43%, and a 5-year Total Return of 52.90%. This stock’s 5-Year Dividend Growth is 0.00%. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in 06/19, Amicus Therapeutics, Inc. (FOLD) reported earnings of -$0.34 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$0.34 per share. In the previous quarter ending in 03/19, the reported earnings of -$0.39 represented a -0.08 difference from the consensus estimate calling for -$0.31 per share, which was a -25.81% surprise.
For the current fiscal quarter, which is set to end in 09/2019, the average earnings estimate is -$0.32 per share. This estimate came from a total of 7 Wall Street Analysts. Of those market experts, the high estimate was -$0.30 and the low estimate was -$0.36. In the year-ago quarter, Amicus Therapeutics, Inc. (FOLD) generated per-share earnings of -$0.31. If the analysts are correct about the current quarter’s earnings, the growth will be -3.23%.
Turning our focus now to insider trading activity, there have been 2 purchases (24,945 shares in total) and 3 sale (41,396 shares in total) in the last 3 months. In the last 6 months, there have been 14 insider buys amounting to 150,362 shares and 12 insider sales amounting to 111,601 shares. In the past full year, 44 insider purchases were made (involving 1,341,885 shares) and 31 insider sell-offs equivalent to 547,353 shares.
Moving onto liquidity, Amicus Therapeutics, Inc. (FOLD) has a Current Ratio of 6.40, a Quick Ratio of 6.30 and a Cash Ratio of 5.85. Looking at this company’s capital structure, its Total Debt to Total Equity is 93.83, its Total Debt to Total Capital is 48.41, and its Total Debt to Total Assets is now 40.73. Looking even further ahead into the future, its Long-Term Debt to Equity is -14.53 and its Long-Term Debt to Total Capital is 93.83.